Triapine
- Generic Name
- Triapine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H9N5S
- CAS Number
- 143621-35-6
- Unique Ingredient Identifier
- U4XIL4091C
- Background
Triapine has been used in trials studying the treatment of Leukemia, Lung Cancer, Kidney Cancer, Prostate Cancer, and Pancreatic Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Triapine in Combination with Temozolomide for the Treatment of Patients with Recurrent Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT06410248
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 94
- Registration Number
- NCT05724108
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy
- Conditions
- Interventions
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT04494113
- Locations
- 🇺🇸
UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
🇺🇸University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT04234568
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer
- Conditions
- Stage II Vaginal Cancer AJCC v6 and v7Stage IVA Vaginal Cancer AJCC v6 and v7Advanced Vaginal AdenocarcinomaAdvanced Vaginal Adenosquamous CarcinomaAdvanced Vaginal Squamous Cell CarcinomaStage IVA Cervical Cancer AJCC v6 and v7Stage IIIB Cervical Cancer AJCC v6 and v7Advanced Cervical AdenocarcinomaAdvanced Cervical Adenosquamous CarcinomaAdvanced Cervical Squamous Cell Carcinoma
- Interventions
- Procedure: Biospecimen CollectionRadiation: BrachytherapyDrug: CisplatinProcedure: Computed TomographyRadiation: External Beam Radiation TherapyOther: Fludeoxyglucose F-18Radiation: High-Dose Rate BrachytherapyRadiation: Intensity-Modulated Radiation TherapyProcedure: Magnetic Resonance ImagingOther: Pharmacological StudyProcedure: Positron Emission TomographyDrug: Triapine
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 21
- Registration Number
- NCT02595879
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
- Conditions
- Advanced Vaginal AdenocarcinomaStage II Cervical Cancer AJCC v7Stage IIB Cervical Cancer AJCC v6 and v7Stage IVA Vaginal Cancer AJCC v6 and v7Unresectable Vaginal CarcinomaVaginal AdenocarcinomaCervical AdenocarcinomaStage IIIB Cervical Cancer AJCC v6 and v7Stage IVA Cervical Cancer AJCC v6 and v7Cervical Adenosquamous Carcinoma
- Interventions
- First Posted Date
- 2015-06-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 450
- Registration Number
- NCT02466971
- Locations
- 🇺🇸
Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States
🇺🇸Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸Ascension Borgess Hospital, Kalamazoo, Michigan, United States
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT00941070
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
3-AP in Treating Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00390052
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- Conditions
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeChronic Eosinophilic LeukemiaBlastic Phase Chronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaEssential ThrombocythemiaPhiladelphia Chromosome Negative Chronic Myelogenous LeukemiaPolycythemia VeraPrimary MyelofibrosisAccelerated Phase Chronic Myelogenous LeukemiaRelapsing Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT00381550
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2013-01-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00335998
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.